Plain-English translation of NCT03966443 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is comparing two different imaging scans — one using a special amino acid tracer and one using a glucose tracer — to see which works better for detecting and monitoring multiple myeloma. Researchers want to understand how these two imaging methods compare in helping doctors diagnose the disease and track how well treatment is working.
Multiple myeloma is a serious blood cancer, and doctors need the best tools to see where the cancer is in the body and how it's responding to treatment. This trial exists to figure out which imaging method gives doctors clearer, more helpful information to guide treatment decisions.
You likely qualify if…
You likely don't qualify if…
You would undergo two different types of imaging scans as part of your regular myeloma evaluation. Both scans are non-invasive and involve receiving a small amount of radioactive tracer before lying still inside a scanner. Your participation helps researchers determine which imaging approach gives the clearest picture of your myeloma.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
Norway
~10 participants
Started
March 2019
Primary completion
January 2020
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2019.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mona-Elisabeth Revheim, MD, PhD, MHA
Oslo University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.